John Seymour

Evaluation of the Impact of Magnetic Resonance Imaging with Susceptibility-weighted Imaging for Screening and Surveillance of Radiation-induced Cavernomas in Long-term Survivors of Malignancy

BA Campbell, A Lasocki, SF Oon, M Bressel, N Goroncy, M Dwyer, K Wiltshire, JF Seymour, K Mason, D Tange, M Xu, G Wheeler

Journal article  |  2021  |  CLINICAL ONCOLOGY

AIMS: Radiation-induced cavernomas (RIC) are common late toxicities in long-term survivors of malignancy following cerebral irradi..

Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.

Thomas E Lew, Victor S Lin, Edward Robert Scheffer Cliff, Piers Blombery, Ella R Thompson, Sasanka Mithila Handunnetti, David A Westerman, Bryone Jean Kuss, Constantine S Tam, David Ching Siang Huang, John F Seymour, Andrew W Roberts, Mary Ann Anderson

Journal article  |  2021  |  Blood Adv

Covalent Bruton tyrosine kinase inhibitors (BTKis) and the BCL2 inhibitor venetoclax have significantly improved outcomes for pati..

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.

Piers Blombery, Thomas E Lew, Michael A Dengler, Ella R Thompson, Victor S Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka Mithila Handunnetti, Dennis Carney, David A Westerman, Constantine S Tam, Jerry M Adams, Andrew H Wei, David Ching Siang Huang, John F Seymour, Andrew Roberts, Mary Ann Anderson

Journal article  |  2021  |  Blood

The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. ..

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.

Matthew S Davids, Andrew W Roberts, Vaishalee P Kenkre, William G Wierda, Abhijeet Kumar, Thomas J Kipps, Michelle Boyer, Ahmed Hamed Salem, John C Pesko, Jennifer A Arzt, Margaret Mantas, Su Y Kim, John F Seymour

Journal article  |  2021  |  Clin Cancer Res

PURPOSE: We previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of r..

Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target

Clare Gould, Jennifer Lickiss, Yamuna Kankanige, Satwica Yemeni, Stephen Lade, Maher K Gandhi, Collin Chin, Costas K Yannakou, Diego Villa, Graham W Slack, John F Markham, Constantine S Tam, Niles Nelson, John F Seymour, Michael Dickinson, Paul J Neeson, David Westerman, Piers Blombery

Journal article  |  2021  |  BRITISH JOURNAL OF HAEMATOLOGY

Richter syndrome (RS), an aggressive lymphoma occurring in the context of chronic lymphocytic leukaemia/small lymphocytic lymphoma..

How I treat chronic lymphocytic leukemia after venetoclax

Thomas E Lew, Constantine S Tam, John F Seymour

Journal article  |  2021  |  BLOOD

Venetoclax-based regimens have expanded the therapeutic options for patients with chronic lymphocytic leukemia (CLL), frequently a..

Should Undetectable Minimal Residual Disease Be the Goal of Chronic Lymphocytic Leukemia Therapy?

Othman Al-Sawaf, John F Seymour, Arnon P Kater, Kirsten Fischer

Journal article  |  2021  |  HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

With the advent of highly effective novel therapies for chronic lymphocytic leukemia, conventional response assessment is not able..

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.

John C Byrd, Peter Hillmen, Paolo Ghia, Arnon P Kater, Asher Chanan-Khan, Richard R Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illés, Neil Kay, Jose A Garcia-Marco, Anthony Mato, Javier Pinilla-Ibarz, John F Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, et al.

Journal article  |  2021  |  J Clin Oncol

PURPOSE: Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized wo..

T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease

Thomas E Lew, Edward RS Cliff, Michael Dickinson, Constantine S Tam, John F Seymour, Piers Blombery, Ashish Bajel, David Ritchie, Amit Khot

Journal article  |  2021  |  BONE MARROW TRANSPLANTATION

Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15

Michael P MacManus, Daniel Roos, Peter O'Brien, Anne Capp, Andrew Wirth, Richard Tsang, Mathias Bressel, Stephen Lade, John F Seymour

Journal article  |  2021  |  EUROPEAN JOURNAL OF CANCER

BACKGROUND: This Phase 2 multicentre trial in localised non-gastric marginal zone lymphoma (MZL) evaluated the effectiveness and s..